Search

Your search keyword '"Lima da Silva, Larissa Soares"' showing total 2 results
Start Over Author "Lima da Silva, Larissa Soares"
2 results on '"Lima da Silva, Larissa Soares"'

1. Occurrence of bisphosphonate-associated osteonecrosis of the jaws in individuals with rheumatoid arthritis - a systematic review.

Author

Tenório, Jefferson R., Estanho, Daniella, Lima da Silva, Larissa Soares, Vaz Braga Pintor, Andréa, Baraúna Magno, Marcela, Leal Cavalcante, Israel, Benevenuto de Andrade, Bruno Augusto, and Cople Maia, Lucianne

Subjects
RHEUMATOID arthritis, OSTEONECROSIS, JAWS, GREY literature, ZOLEDRONIC acid
Abstract

Background: To access the occurrence of bisphosphonate-associated osteonecrosis of the jaw (BAONJ) in individuals with rheumatoid arthritis (RA). Material and Methods: Observational studies that evaluated the occurrence of BAONJ in individuals with RA (BAONJ-RA) were considered for inclusion. Electronic searches were performed up to December 2022 in six databases and in the grey literature. The study selection, data extraction, and quality assessment of the included studies according to the Joanna Briggs Institute Critical Appraisal Checklists was performed. The certainty of evidence was evaluated using the GRADE approach. Results: Five studies were included three cohort and two cross-sectional. The sample size of subjects with RA ranged from 16 to 3201. Together, the studies presented 36 cases of BAONJ-RA. Prevalence of BAONJ-RA ranged from 0.094% to 56.25%. The incidence ranged from 0.4% to 2.21. Women between the 6th and 8th decade of life were the most affected. Alendronate (n=5) and zoledronic acid (n=9), orally and intravenously, respectively, were the most used bisphosphonates. The duration of bisphosphonates use ranged from 2.7 to 8 years. The certainty of evidence was very low. Conclusions: The occurrence of BAONJ-RA is low. However, the certainty of the evidence was very low for this outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Lesions in the oral mucosa associated with the use of checkpoint inhibitors: A bibliometric and critical review.

Author

Jural, Lucas Alves, Estanho, Daniella, Pereira, Juliana da Silva Rangel, Ribeiro‐Lages, Mariana Batista, Lima da Silva, Larissa Soares, Cavalcante, Israel Leal, Maia, Lucianne Cople, Andrade, Bruno Augusto Benevenuto de, and Tenório, Jefferson R.

Subjects
DRUG side effects, IMMUNE checkpoint inhibitors, ORAL mucosa, BIBLIOMETRICS, NIVOLUMAB
Abstract

Aims: Immune‐related adverse events (irAEs) linked to the use of immune checkpoint inhibitors (ICIs) have become increasingly frequent. To perform a bibliometric and critical review of the general panorama of publications on oral mucosal lesions (OML) associated with ICIs. Methods and Results: Systematized searches were performed in four databases. The included studies were organized and bibliometric and clinical data were extracted and analyzed using VantagePoint and Microsoft Excel. Most of the 35 included studies were reports or case series (n = 33/94.2%). The American authors stood out (n = 17/48.5%), with the majority presenting only one publication. Independent groups carried out most of the publications (n = 31/88.5%). Over the years, publications have increased for users of nivolumab and pembrolizumab. In 21 studies (60%), OML were more common in men, between the 6th and 9th decades of life and who had lung carcinoma (n = 13/37.1%). Pembrolizumab (n = 17/48.5%) was the most used ICI. The patients were affected by one or more OML, including: ulcers (n = 28/80%) and erythema (n = 11/31.4%). Systemic corticosteroids (n = 24/68.5%) and the discontinuation of ICI use (n = 18/51.4%) were the main approaches used. Conclusion: OML related to the use of ICIs have become increasingly common. More accurate data need to be published. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results